David Ledbetter is chief clinical officer of Dascena, a personalized medicine company.
David Ledbetter
Chief clinical officer
Dascena
From this contributor
There are no autism-specific genes, just brain genes
There is not yet a single example of a gene that, when mutated, increases the likelihood of autism but not of other neurodevelopmental conditions, including intellectual disability.
There are no autism-specific genes, just brain genes
By
David Ledbetter, Scott Myers
23 March 2021 | 5 min read
Developmental disorders should be viewed as continuum
Intellectual disability, autism, epilepsy and schizophrenia should be considered part of a spectrum of developmental brain dysfunction, says David Ledbetter.
Developmental disorders should be viewed as continuum
By
David Ledbetter
6 May 2013 | 5 min read
Explore more from The Transmitter
Cell population in brainstem coordinates cough, new study shows
The work also adds to a growing body of evidence showing that mice, and their genetic toolbox, can be used to study cough.
Cell population in brainstem coordinates cough, new study shows
The work also adds to a growing body of evidence showing that mice, and their genetic toolbox, can be used to study cough.
By
Calli McMurray
6 September 2024 | 5 min read
In updated U.S. autism bill, Congress calls for funding boost, expanded scope
The current Autism CARES Act sunsets in late September.
In updated U.S. autism bill, Congress calls for funding boost, expanded scope
The current Autism CARES Act sunsets in late September.
By
Rachel Zamzow
5 September 2024 | 5 min listen
Ketamine targets lateral habenula, setting off cascade of antidepressant effects
The drug’s affinity for overactive cells in the “anti-reward” region may help explain its rapid and long-lasting results.
Ketamine targets lateral habenula, setting off cascade of antidepressant effects
The drug’s affinity for overactive cells in the “anti-reward” region may help explain its rapid and long-lasting results.
By
Olivia Gieger
4 September 2024 | 6 min read